Identification of Naturally Processed HLA-A2—Restricted Proinsulin Epitopes by Reverse Immunology

  1. Yousra Hassainya1,
  2. Francisco Garcia-Pons2,
  3. Roland Kratzer1,
  4. Vivian Lindo3,
  5. Fiona Greer3,
  6. François A. Lemonnier2,
  7. Gabriele Niedermann4 and
  8. Peter M. van Endert1
  1. 1Institut National de la Santé et de la Recherche Médicale Unité 580, Université René Descartes, Paris, France
  2. 2Unité d’Immunité Cellulaire Antivirale, Département d’Immunologie, Institut Pasteur, Paris, France
  3. 3M-SCAN, Wokingham, U.K
  4. 4Department of Cellular Immunology, Max Planck Institute of Immunobiology, Freiburg, Germany
  1. Address correspondence and reprint requests to Dr, Peter van Endert, INSERM U580, Hôpital Necker, 161 rue de Sèvres, 75743 Paris, Cedex 15, France. E-mail: vanendert{at}necker.fr

Abstract

Type 1 diabetes is thought to result from the destruction of β-cells by autoantigen-specific T-cells. Observations in the NOD mouse model suggest that CD8+ cytotoxic T-cells play an essential role in both the initial triggering of insulitis and its destructive phase. However, little is known about the epitopes derived from human β-cell autoantigens and presented by HLA class I molecules. We used a novel reverse immunology approach to identify HLA-A2−restricted, naturally processed epitopes derived from proinsulin, an autoantigen likely to play an important role in the pathogenesis of type 1 diabetes. Recombinant human proinsulin was digested with purified proteasome complexes to establish an inventory of potential COOH-terminals of HLA class I−presented epitopes. Cleavage data were then combined with epitope predictions based on the SYFPEITHI and BIMAS algorithms to select 10 candidate epitopes; 7 of these, including 3 with a sequence identical to murine proinsulin, were immunogenic in HLA-A2 transgenic mice. Moreover, six of six tested peptides were processed and presented by proinsulin-expressing cells. These results demonstrate the power of reverse immunology approaches. Moreover, the novel epitopes may be of significant interest in monitoring autoreactive T-cells in type 1 diabetes.

Footnotes

    • Accepted April 12, 2005.
    • Received December 23, 2004.
« Previous | Next Article »Table of Contents